CMAB007 clinical trials
Also written CMAB007.
How each study uses CMAB007 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CMAB007
- 3
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Taizhou Mabtech Pharmaceutical Co.,Ltd (2) · Shanghai Biomabs Pharmaceutical Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses CMAB007 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous UrticariaCompletedPhase 3Taizhou Mabtech Pharmaceutical Co.,LtdNCT06365879Written as CMAB007
- The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and ImmunogenicityCompletedPhase 1Taizhou Mabtech Pharmaceutical Co.,LtdNCT05897008Written as CMAB007
- Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.CompletedPhase 3Shanghai Biomabs Pharmaceutical Co., Ltd.NCT03468790Written as CMAB007